Picture of Ashland logo

ASH — Ashland News Story

0.000.00%
us flag iconLast trade - 00:00
Basic MaterialsBalancedLarge CapNeutral

Ashland Q3 revenue down 15%, misses estimates

Overview

Ashland fiscal Q3 revenue down 15%, missing analyst expectations, per LSEG data

Adjusted EPS for fiscal Q3 misses consensus, reflecting demand challenges and portfolio optimization

Net loss of $742 million primarily due to non-cash goodwill impairment charge

Outlook

Ashland expects FY2025 sales of $1.825 bln to $1.850 bln

Company projects FY2025 Adjusted EBITDA of $400 mln to $410 mln

Ashland sees stable macro environment with mixed demand trends

Tariff-related uncertainty persists, no material FY2025 impact expected

Result Drivers

PORTFOLIO OPTIMIZATION - Initiatives reduced sales by $53 mln, impacting revenue and adjusted EBITDA

SOFTER DEMAND - Personal Care and Specialty Additives faced subdued demand, contributing to revenue decline

PHARMA GROWTH - Life Sciences segment maintained growth momentum in pharma applications despite overall sales decline

Key Details

MetricBeat/MissActualConsensus Estimate
Q3 RevenueMiss$463 mln$476.40 mln (7 Analysts)
Q3 Adjusted EPSMiss$1.04$1.23 (9 Analysts)
Q3 EPS-$16.21
Q3 Net Income-$742 mln
Q3 Adjusted EBITDAMiss$113 mln$115.10 mln (10 Analysts)
Q3 Free Cash Flow$108 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell" The average consensus recommendation for the diversified chemicals peer group is "buy" Wall Street's median 12-month price target for Ashland Inc is $62.00, about 17.8% above its July 28 closing price of $50.95 The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago Press Release: ID:nGNX7CxwPC (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Ashland

See all news